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Gastric cancer screening by combined assay for serum anti-Helicobacter
pylori IgG antibody and serum pepsinogen levels—“ABC method”
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Abstract: The current status of screening for gastric cancer-risk (gastritis A, B, C, D)
method using combined assay for serum anti-Helicobacter pylori (Hp) IgG antibody and serum
pepsinogen (PG) levels, “ABC method”, was reviewed and the latest results of our ongoing trial are
reported. It was performed using the following strategy: Subjects were classiﬁed into 1 of 4 risk
groups based on the results of the two serologic tests, anti-Hp IgG antibody titers and the PG I and
II levels: Group A [Hp(!)PG(!)], infection-free subjects; Group B [Hp(D)PG(!)], chronic atrophic
gastritis (CAG) free or mild; Group C [Hp(D)PG(D)], CAG; Group D [Hp(!)PG(D)]), severe CAG
with extensive intestinal metaplasia. Continuous endoscopic follow-up examinations are required to
detect early stages of gastric cancer. Asymptomatic Group A, which accounts for 50–80% of all the
subjects may be excluded from the secondary endoscopic examination, from the viewpoint of
eﬃciency. Hp-infected subjects should be administered eradication treatment aimed at the
prevention of gastric cancer.
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Introduction
In 2010, gastric cancer remains one of the most
important gastrointestinal cancers. It is the fourth
most common cancer and second leading cause of
cancer deaths (700,000 deaths annually) worldwide.1)
In 2002, an estimated one million new cases of gastric
cancer were diagnosed, with almost two-thirds
occurring in developing countries. High-risk areas
include East Asia (Japan, China), Eastern Europe
and parts of Central and South America.2)
It is important to introduce an eﬃcient and cost-
eﬀective practical mass screening method for early
detection of gastric cancer. It may be possible to
reconstitute the screening system of gastric cancer
according to the risk level, so that unnecessary
annual invasive screening examinations are avoided.
It is well established that gastric carcinogenesis
is a continuous process starting from superﬁcial
gastritis to the development of glandular atrophy,
metaplasia and dysplasia, and ﬁnally, adenocarcino-
ma.3) This process usually takes decades and seems to
be initiated by infection with the gastric bacterium,
Helicobacter pylori (Hp)4) in many, if not most cases.
The long history of the disease process potentially
provides opportunities for early detection of pre-
cancerous lesions and consequent appropriate inter-
vention. The application of strategies directed
towards the elimination of risk factors is of para-
mount importance in the control of gastric cancer.5)
The high prevalence of intestinal metaplasia
among Hp-infected patients suggests that the risk of
development of gastric cancer will continue to remain
high. Since gastric cancer is potentially curable if
diagnosed early, it is insuﬃcient to check for Hp
antibody titers alone for the diagnosis of subjects
with severe atrophic gastritis. The serum pepsinogen
test method, or the “PG method”6)–19) is also needed
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who do not have atrophic gastritis or Hp infection
can be screened by the combination of the PG
method and Hp serology, or the screening for gastric
cancer-risk (gastritis A, B, C, D) method or the “ABC
method”.
Here, the author reviews the present status of
gastric cancer screening using the ABC method,
including the latest results of our ongoing trial.
Gastric cancer and Hp infection
The discovery of Hp in 1982 has not only
changed the concept of upper gastrointestinal tract
diseases, but also of clinical gastroenterological
practice.4) Results of clinical and basic research
accumulated over the last decade clearly demonstrate
the existence of a close relationship between Hp
infection and the risk of gastric cancer.20)–34) Hp
infection is now recognized as the main acquired
factor involved in the pathogenesis of peptic ulcer
disease and chronic gastritis, as also gastric cancer.20)
Gastric cancer almost never occurs in the ab-
sence of Hp infection. Observation of 1,526 individ-
uals over a period of 10 years revealed that gastric
cancer was found in 5% of all individuals infected
with Hp and in none of the uninfected individuals.28)
Uemura N. et al.25) followed up patients who
underwent endoscopic therapy for gastric cancer that
resulted in complete cure, and compared the in-
cidence rate of gastric cancer at another site in the
stomach (metachronous gastric cancer) between
patients who were and were not treated with an Hp
eradication regimen. During the 54-month follow-up
period, metachronous gastric cancer was not found
in any of the patients administered Hp eradication
treatment, but in 10% of those who did not receive
the eradication therapy. Over longer periods, how-
ever, occurrence of gastric cancer was also detected
among the patients who had received Hp eradication
therapy, however, the incidence was clearly lower
than that in the patients who had not received Hp
eradication therapy. Other reports30) lend support to
these ﬁndings.
Eradication of Hp decreases the severity of
gastritis, producing signiﬁcant changes in the serum
PG levels; both serum PG I and PG II levels decrease,
with elevation of the PG I to PG II ratio.35)–38)
Furuta T. et al.35) determined the optimal cutoﬀ
values for the percent change of the serum PG I/II
ratio. The cutoﬀ was tentatively set as D40%, D25%,
and D10% when the serum PG I/II ratios before
treatment were less than 3, equal to or greater than 3,
but less than 5, and equal to or greater than 5,
respectively. Since the method involving determina-
tion of the percent change of the serum pepsinogen
levels has the advantage that no endoscopy is
required, repeated examinations will be more accept-
able to the patients. Thus, the serological method
may be a useful non-invasive method for determining
eradication of Hp.
Hp antibody titers39) vary greatly depending on
the test kit used in Japan. Use of an Hp antibody test
kit with Japanese strains without an indeterminate
range is recommended.
The PG method
Serum pepsinogen (PG)40)–42) is classiﬁed into
two biochemically and immunologically distinct
types, namely, PG I and PG II.43)–47) PG I is produced
by the chief and mucous neck cells in the fundic
glands, while PG II is produced by these cells and also
by the cells in the pyloric glands and Brunner’s
glands. It is widely accepted that the serum PG levels
reﬂect the functional and morphologic status of the
stomach mucosa. As the fundic gland mucosal area
reduces, the PG I levels gradually decrease, while
the PG II levels remain fairly constant. As the result,
a stepwise reduction of the PG I/II ratio is closely
correlated with the progression from normal gastric
mucosa to extensive atrophic gastritis.6)–19)
Serum PG was used as a biomarker of the gastric
mucosal status, including to detect atrophic changes
and inﬂammation, before the discovery of Hp.
PG is a serum marker of atrophic gastritis,
which is a precancerous change in the stomach,
rather than being a tumor marker.13),14) The PG
method6)–19),48)–74) allows the diagnosis of advanced
atrophic gastritis, a high risk factor for gastric cancer,
and can be applied to gastric cancer screening using
the serum PG I level and PG I/II ratio as indices,
based on the association between CAG and gastric
cancer, and the correlation between the serum PG
levels and the presence of CAG. Thus, for the
detection of gastric cancer, patients at high risk for
gastric cancer have been screened clinically by the
PG method.11)–15)
In 10-year follow-up studies, from 1992 to 2001,
of 882 individuals from a Tokyo Teishin Hospital
Health Care Center in Japan, where screening for
gastric cancer by the PG method and endoscopy is
practiced, Kaplan–Meier survival estimates stratiﬁed
by age revealed no reduction of the cumulative
survival estimate during 4 years in individuals in
their 40’s, 50’s and 60’s63),64) (Fig. 1).
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municipality of Hiroshima prefecture in Japan, the
number of reported deaths from gastric cancer was
41. In a case-control study based on the 41 deaths
and 3 controls, the odds ratio (95% CI) for death
within 3 years after screening by the PG method
was 0.290 (0.0111–0.759), indicating the potential
contribution of the PG method to a signiﬁcant
reduction of gastric cancer mortality within 3 years63)
(Table 1).
The PG method identiﬁes atrophic gastritis, a
high-risk factor for gastric cancer, and therefore, may
be called a mass screening test method for gastric-
cancer-risk, rather than as one for gastric cancer
itself.
It is of great signiﬁcance to detect early gastric
cancer by screening of high-risk patients detected
using the PG method and following the patients
up by endoscopy on a regular basis. As reported
elsewhere,15) we have obtained good results of the
mass screening system using the PG method alone.
However, a controversial and the most impor-
tant weak point in the mass screening system by the
PG method alone is the presence of the PG method-
negative gastric cancer, especially, diﬀuse-type gas-
tric cancer.
Although it is possible to detect such cancers by
an endoscopic examination once in 5 years,15) patients
will beneﬁt from screening by the less invasive
combination of the PG method and serum anti-Hp
antibody assay, the “ABC method”,39),75),76) which
can also detect PG method-negative gastric cancer.
We have conﬁrmed that the ABC method is
useful for the detection of both the intestinal and
diﬀuse types of gastric cancer from the residual serum
samples of 51 gastric cancer cases found among
43,438 subjects who had undergone screening as part
of a health checkup at a certain workplace from the
year 2000 to 2005;63) of the total, 7 cases were PG
method-negative and Hp serology-positive. There-
after, we decided to introduce the ABC method at
this work place in Tokyo for the ﬁrst time.
Fig. 1. Accumulated survival rate for each age-group by the PG method using Kaplan–Meier analysis at Tokyo Teishin Hospital Care
Center in Tokyo for the ten-year period (1992–2001); n F 88263),64)
Table 1. Evidence of a decrease in gastric cancer mortality by
the PG method at a municipality of Hiroshima Prefecture using







Visit within 1 year 0.238 (0.061–0.929) 41
Visit within 2 years 0.375 (0.155–0.905) 41
Visit within 3 years 0.290 (0.111–0.759) 36
Visit within 4 years 0.423 (0.164–1.091) 32
Visit within 5 years 0.440 (0.171–1.135) 31
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by the ABC method39)
Results of much basic research suggest that Hp
infection is closely associated with the development
of gastric cancer.4),5) Domestic74),77)–80) and foreign
epidemiological studies also lend support to the
notion that Hp infection is a risk factor for gastric
cancer, except that the odds ratio varied from study
to study. It has also become evident that atrophy
of the gastric mucosa is a high-risk factor for the
development of gastric cancer, and that the serum
PG levels are correlate with atrophy of the gastric
mucosa. The ABC method allows stratiﬁcation
of risk for the development of gastric can-
cer.24),26),29),34),57),72) Other reports69)–71),81) from Jap-
anese researchers also support these ﬁndings.
Cohort studies57) in 4,655 normal male individ-
uals who could be followed up for at least 10 years
show that gastric cancer developed only in individ-
uals infected with Hp and did not develop in normal
individuals testing negative for Hp. As chronic
gastritis progressed, a gradual and signiﬁcant in-
crease in the incidence of gastric cancer and hazard
ratio was noted (Table 2). The most advanced and
severe cases of gastric atrophy judged by the pepsin-
ogens assessment, when combined with a negative Hp
serology, probably due to a Hp antibody spontaneous
disappearance,54),57) was associated when an even
greater progression to dysplasia and cancer.
Of 8,286 individuals of Matsue city in Japan who
underwent endoscopic screening for gastric cancer
during health checkup in which Hp antibodies were
measured in addition to the PG method, 2,802
were classiﬁed as group A [Hp(!)PG(!)], 3,395 as
group B [Hp(D)PG(!)], and 2,089 as group C
[Hp(D)PG(D) and Hp(!)PG(D)].81) According to a
follow-up over the subsequent 14 years, gastric cancer
occurred in 46 individuals in Group C (1.87%) and 7
individuals in Group B (0.21%), while there were no
cases from Group A. Therefore, we can discriminate
between low-risk and high-risk groups for the
development of gastric cancer using the ABC
method.
The above results show that (1) the risk of
gastric diseases is very low in individuals with a
healthy gastric mucosa (Group A), (2) there is an
elevated risk of peptic ulcer, etc., in Group B, (3)
individuals in Group C are at a higher risk of
developing diseases resulting from atrophy of the
gastric mucosa, such as gastric cancer, gastric
adenoma and hyperplastic polyps, and (4) individu-
als in Group D [Hp(!)PG(D)], with advanced
atrophy, are at a higher risk of developing gastric
cancer. The risk of gastric cancer is highest in
Group D, followed by that in Groups C, B, and A,
in descending order.34),57),63),64)
The ABC method allows stratiﬁcation of the risk
for the development of gastric cancer into four (A, B,
C, and D) groups. The advantages of this examina-
tion are as follows: (1) Serum PG levels do not vary
greatly within 10 years or so in more than 90% of
adults, (2) Hp infection is originally acquired in
childhood in most cases, (3) the antibody titer is
relatively stable in people aged 40 years or older, and
(4) this examination can be performed simultane-
ously with a regular health checkup.
If individuals are classiﬁed into a high-risk group
or low-risk group through primary screening using
the ABC method, it may be possible to reconstitute
the screening system for gastric cancer according to
the risk level of the patients, instead of implementing
annual screening for all individuals.
Ongoing trial of the ABC method in Tokyo
Since 1991, we have been performing mass
screening for gastric cancer risk.11),15) The mass
screening system consists of primary screening of
high-risk-employees for gastric cancer using serum
samples and secondary examination by endoscopy
among those presenting for a health-checkup.
We initiated the ABC method in 2007, in which
people in group A are advised to have endoscopic
examination every ﬁve years, those in group B every
three years, those in group C every two years, and
those in group D annually. During the three years
from 2007 to 2009, we examined a total of 48,073
individuals after excluding those who met the
Table 2. Incidence of gastric cancer and hazard ratio associated
with atrophic gastritis at a workplace in Wakayama Prefecture
for the eight-year periods (1994–2002); n F 5,20939)
Group* A B′ BC C ′ D
Number of individuals 966 501 2,327 1,329 53 33
Person-year 9,487 5,007 22,436 12,665.5 524.5 306
Mean age (years) 48.3 46.8 49.5 50.4 47.9 49.3
Follow-up period
(years)
9.8 10.0 9.6 9.5 9.9 9.3
Incidence of gastric
cancer
0 1 25 30 3 4
Hazard ratio 1 2.1 9.8 19.6 54.8 120.4
*Group: A: Hp(!)PG(!), B′: Hp(’)PG(!), B: Hp(D)PG(!),
C: Hp(D)PG(D), C′: Hp(’)PG(D), D: Hp(!)PG(D).
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Serum samples collected at the time of the
general health checkup were used to measure the
serum PG I and II levels (LZ test, ‘Eiken’ Pepsinogen
I and II: LA; latex agglutination method) and serum
anti-Hp antibody (E-plate ‘Eiken’ H. pylori anti-
body: EIA; enzyme immunoassay method). Individ-
uals with PG I levels of 570µg/l and PG I/II ratio of
53 were classiﬁed as PG-positive, and those with a
serum Hp antibody titer of 610U/ml were classiﬁed
as Hp-positive.
Based on the results of the above tests, the
subjects were classiﬁed into the following four groups:
group A [Hp(!)PG(!)], group B [Hp(D)PG(!)],
group C [Hp(D)PG(D)], and group D [Hp(!)PG(D)],
respectively. There were 35,177 individuals in
group A, 7,883 individuals in group B, 4,489 indi-
viduals in group C, and 524 individuals in group D.
Based on the time of the most recent endoscopic
examination, 6,965 of all the individuals were advised
to undergo endoscopic examination, and 3,921 (56%)
actually underwent endoscopy76) (Table 3).
Of the 3,921 individuals, 23 were found to have
gastric cancer (detection rate of gastric cancer:
0.05%, positive predictive value: 0.59%). Five of
them were found to have advanced cancer, and it was
the ﬁrst time for all of them to have undergone
screening for gastric cancer risk by the ABC method,
for reasons such as mid-career hiring. The remaining
18 (78%) had early gastric cancer and 12 (52%) had
intestinal-type gastric cancer. Endoscopic resection
was performed in 12 of the patients (52%), and
radical surgical resection was possible in the remain-
ing 11 individuals, including those with advanced
cancer. Histopathologically, 48% of the detected
cancers were of the diﬀuse type, with the ratio of
the diﬀuse type increasing gradually over the years
(25% in 2007, 63% in 2008, and 100% in 2009).
From 2007 to 2009, individuals in group A (low-
risk group), accounting for 73% of all the individuals,
were excluded from the secondary endoscopic exami-
nation, to resolve the shortage of manpower, which
resulted in successful examination of the risk of
gastric cancer.
The percentages of people in group A in 2007,
2008, and 2009 were 71%, 73%, and 76%, and those
in group B were 19%, 17% and 14%, respectively.
Consequently, the annual rate of increase of group A
subjects was estimated to be about 3% and the rate
of decrease of group B was estimated to be about 3%
per year. The number of individuals in group A will
continue to increase at the rate of about 3% per year,
which is expected to contribute to a further reduction
in the number of individuals who are advised to
undergo mass screening examination for gastric
cancer in the future.76)
It remains to be seen whether the ABC
method,39),75),76),82) which was introduced in 2007
and has been studied for only 3 years, is eﬀective.
Because 70% of the patients with gastric cancer
have been found in group B, for which endoscopic
examination would have been performed only once
in 5 years by the conventional PG method, the ABC
method is likely to detect PG-negative gastric cancer
at an early stage.
It is also suggested that the ABC method, which
also allows detection of diﬀuse-type gastric cancers
and successful endoscopic resection, can reliably
detect gastric cancer earlier. However, as I will
mention the weak points and points of caution of
the ABC method later in the appendix of this
manuscript, there are several problems for adopting
the ABC method in clinical practice for primary
gastric cancer screening, especially to exclude Hp-
infected individuals from group A.
At present, it is still too early for us to draw any
deﬁnitive conclusions, but the ABC method should
Table 3. Subjects of “the ABC method” at a work place in Tokyo for three-year periods (2007–2009)76)
Total number of 3 years 2007 year 2008 year 2009 year
Screened case 48,073 (100%) 15,043 (100%) 16,080 (100%) 16,950 (100%)
Group A* 35,177 (73%) 10,628 (71%) 11,696 (73%) 12,853 (76%)
B* 7,883 (17%) 2,911 (19%) 2,681 (17%) 2,291 (14%)
C* 4,489 (9%) 1,374 (9%) 1,527 (9%) 1,588 (9%)
D* 524 (1%) 130 (1%) 176 (1%) 218 (1%)
Requiring endoscopy 6,965 (15%) 3,346 (22%) 2,154 (13%) 1,465 (9%)
Underwent endoscopy 3,921 (8%) 1,627 (11%) 1,535 (10%) 759 (4%)
*Group: A: Hp(!)PG(!), B: Hp(D)PG(!), C: Hp(D)PG(D), D: Hp(!)PG(D).
Group A is excluded from the secondary endoscopic examination from the view point of eﬃciency.
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gastric cancer risk suitable for the circumstances in
Japan, where the number of people infected with Hp
or testing positive for PG is decreasing. It is hoped
that more experience will be accumulated at many
institutions besides this clinic in Japan, as well as in
other countries across the world.
Conclusion
Although there is still room for improvement of
the ABC method, I think it is useful to select high-
risk and low-risk populations for development of
gastric cancer, and to detect not only the intestinal
type, but also the diﬀuse type of gastric cancers in the
early stage. I believe it can be a step towards reaching
the ultimate goal of mass screening, that is,
eradication of gastric cancer.
Appendix
Technical recommendations for adopting the
ABC method39)
1. According to the ABC method, it is recom-
mended that the risk for gastric cancer be
stratiﬁed into four groups according to the anti-
Hp IgG antibody titer before eradication of Hp
and the serum PG levels, as follows: group A
[Hp(!)PG(!)], group B [Hp(D)PG(!)], group C
[Hp(D)PG(D)], and group D [Hp(!)PG(D)].
For the PG method, the cutoﬀ points for
identifying the risk of gastric cancer should be
570µg/l for pepsinogen I and 53 for the PG
I/II ratio, and inquiries about a history of Hp
eradication, previous treatment of peptic ulcer
(especially, treatment with PPIs), previous
gastric resection, and impairment of renal
function are essential.
2. PG levels do not vary from one test kit to
another, whereas Hp antibody titers vary
greatly depending on the test kit used in Japan.
Use of an Hp antibody test kit with Japanese
strains without an indeterminate range is
recommended.
3. To exclude Hp-infected individuals from group
A:
(1) Measures for individuals who have received
Hp eradication: What is most important is an
inquiry about a history of Hp eradication. If
serum PG levels change signiﬁcantly or both
serum PG I and PG II levels are low, it may
be assumed that the person has received Hp
eradication therapy. (2) Measures for individu-
als who are false-negative for Hp antibody: It is
highly likely that elevated PG levels, especially
a PG II level of 615µg/l, reﬂect the presence of
histological gastritis associated with Hp infec-
tion. In this case, the presence of Hp should be
checked using other antibodies or test methods.
(3) Measures for individuals in whom Hp
infection resolved spontaneously: low PG levels,
especially a PG I level of 535µg/l and PG I/II
ratio of 4.0 to 3.1, may indicate the possibility
of previous infection with Hp or spontaneous
resolution of Hp infection.
4. The interval for screening by the ABC method
need not be yearly, and an interval of 5 years
or so is recommended. It is recommended that
endoscopic examination be performed at least
once every 3 years for group B, at least once
every 2 years for group C, and annually for
group D, and that group A be excluded from
the examination.
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